About Melio
Melio is a Healthcare company based in Santa Clara (United States) founded in 2018 by Shelley Lawrence, Stephanie Fraley, and Mridu Sinha. It operates as a blood-based pathogen detection devices are manufactured for healthcare applications. It operates on a HealthTech model. Melio has raised $4.25 million across 3 funding rounds from investors including IndieBio and LongeVC. Its chief executive is Mridu Sinha. Melio offers products and services including Melio Diagnostic Platform. Its focus areas include Medical Devices and Diagnostic Equipment. Its legal entity is Melio, Inc.
Company details
A culture-free, rapid, and comprehensive blood testing platform is developed by Melio to identify pathogens in hours instead of days. Focus is placed on critical applications such as newborn care in NICUs, where timely diagnosis is essential. Advanced systems engineering, microfluidics, and machine learning are integrated to ensure faster and precise treatments. The technology is designed to adapt and detect newly emerging pathogens, expanding its diagnostic database. Solutions are aimed at addressing global challenges like antibiotic resistance within the healthcare sector.
- Headquarters Santa Clara, United States
- Founders Shelley Lawrence, Stephanie Fraley, Mridu Sinha
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website melio.tech
- Social LinkedIn
- Legal Name Melio, Inc.
- Total Equity Funding$4.25M (USD)
in 3 rounds
- Latest Funding Round$4M (USD), Series A
Jun 2024
- InvestorsIndieBio
& 1 more
Products & Services of Melio
Melio offers a comprehensive portfolio of products and services, including Melio Diagnostic Platform.
Bloodborne pathogen testing is delivered rapidly and accurately.
Funding Insights of Melio
Melio has successfully raised a total of $4.25M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.25M
- Total Rounds 3
- Last Round Series A — $4M
- First Round $250,000
(Dec 2022)
- Investors Count 2
All 3 funding rounds of Melio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Melio
Melio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include IndieBio and LongeVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are accelerated through IndieBio's focused programs. | – | indiebio.co | San Francisco, United States | |
LongeVC is focused on venture capital investments in biotech. | – | longevc.com | - |
Investor details for Melio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Melio
20 people are tracked at Melio (8 in leadership, 9 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Shelley Lawrence | Co-Founder | Leadership |
Stephanie Fraley | Co-Founder | Leadership |
Mridu Sinha | Founder & CEO | Leadership |
Evan Foster | Director, Systems Architecture And Integration | Leadership |
Luc Bousse | Senior Director Of Microfluidics And Systems Integration | Leadership |
Artem Trotsyuk | Head of Business Affairs | Leadership |
Todd Peterson | Head of Product Development | Leadership |
Clare Fasching | Director Assay Development | Leadership |
Ryan Simkovsky | Scientific Advisor | Board & advisors |
Claude Benchimol | Business Advisor | Board & advisors |
Todd Coleman | Scientific Advisor | Board & advisors |
Daniel Schmitigal | Business Advisor | Board & advisors |
Ravi Jain | Advisor | Board & advisors |
Anula Jayasuriya | Advisor | Board & advisors |
Ramon Felciano | Advisor | Board & advisors |
Ravi Mistry | Advisor | Board & advisors |
Shrabani Jain | Advisor | Board & advisors |
Saurabh Mehta | Full Stack Developer | Team |
Himanshu Chittora | Full Stack ML Engineer | Team |
Julia Wellons | Research Associate | Team |
Complete people profiles for Melio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Melio
3 dated milestones of Melio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Melio is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series A, of $4.0M.
Web traffic of Melio
The website of Melio (melio.tech) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 26.9% vs previous month
Top companies in Traditional Diagnostics & Medical Devices
10 companies that operate in the same segment as Melio (Traditional Diagnostics & Medical Devices), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Materials management solutions are provided for healthcare organizations. | 1892 | Chicago, Illinois, United States | USD 29.13 M | USD 20.63 B | 53,000 | |
3D-printed orthopedic products are manufactured for medical applications. | 1941 | Kalamazoo, Michigan, United States | – | – | – | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Heart pumps are developed for blood circulation and oxygenation support. | 1981 | Danvers, Massachusetts, United States | – | USD 1.03 B | 1,157 | |
Medical device management services are provided to healthcare facilities. | 1999 | Exeter, New Hampshire, United States | USD 275.93 M | USD 68.67 M | 353 | |
Medical surgical consumables including sutures and anti-microbial gloves are manufactured. | 1992 | Bengaluru, Karnataka, India | – | USD 7.14 K | 39 | |
Manufacturer of medical equipments | 1967 | Bengaluru, Karnataka, India | USD 58.9 M | USD 98.65 M | 578 | |
BD is recognized for providing innovative medical technology solutions. | 1897 | Franklin Lakes, New Jersey, United States | – | USD 21.84 B | 74,000 | |
Dental lasers and scanning devices are developed for clinical use. | 1987 | Foothill Ranch, California, United States | – | USD 49.16 M | – | |
Manufacturer and distributor of aprons, surgical gowns, uniforms, and other medical products | 1966 | Mundelein, Illinois, United States | – | USD 28.45 B | 1,305 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Melio
Melio was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Melio is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Mridu Sinha is the current CEO of Melio. They have also founded this company.
Melio is a funded company, having raised a total of $4.25M across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Dec 2022.
A culture-free, rapid, and comprehensive blood testing platform is developed by Melio to identify pathogens in hours instead of days. Focus is placed on critical applications such as newborn care in NICUs, where timely diagnosis is essential. Advanced systems engineering, microfluidics, and machine learning are integrated to ensure faster and precise treatments. The technology is designed to adapt and detect newly emerging pathogens, expanding its diagnostic database. Solutions are aimed at addressing global challenges like antibiotic resistance within the healthcare sector.
Melio offers Melio Diagnostic Platform.
Melio has 2 investors. Key investors include IndieBio, and LongeVC.
Melio operates through Melio, Inc..